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Background: The relationship between the uptake of [18F]fluoroerythronitroimidazole ([18F]FETNIM), blood flow
([15O]H2O) and 2-[
18F]fluoro-2-deoxyglucose ([18F]FDG) and immunohistochemically determined biomarkers was
evaluated in squamous-cell carcinomas of the head and neck (HNSCC).
Methods: [18F]FETNIM and [18F]FDG PET were performed on separate days on 15 untreated patients with HNSCC.
Hypoxia imaging with [18F]FETNIM was coupled with measurement of tumor blood flow using [15O]H2O. Uptake of
[18F]FETNIM was measured as tumor-to-plasma ratio (T/P) and fractional hypoxic volume (FHV), and that of [18F]FDG
as standardized uptake value (SUV) and the metabolically active tumor volume (TV). Tumor biopsies were cut and
stained for GLUT-1, Ki-67, p53, CD68, HIF-1α, VEGFsc-152, CD31 and apoptosis. The expression of biomarkers was
correlated to PET findings and patient outcome.
Results: None of the PET parameters depicting hypoxia and metabolism correlated with the expression of the
biomarkers on a continuous scale. When PET parameters were divided into two groups according to median values,
a significant association was detected between [18F]FDG SUV and p53 expression (p =0.029) using median SUV as
the cut-off. There was a significant association between tumor volume and the amount of apoptotic cells (p =0.029).
The intensity of VEGF stained cells was associated with [18F]FDG SUV (p =0.036). Patient outcome was associated with
tumor macrophage content (p =0.050), but not with the other biomarkers. HIF-1α correlated with GLUT-1 (rs =0.553,
p =0.040) and Ki-67 with HIF-1α (rs =506, p =0.065). p53 correlated inversely with GLUT-1 (rs = −618, p =0.019) and
apoptosis with Ki-67 (rs = −638, p =0.014).
Conclusions: A high uptake of [18F]FDG expressed as SUV is linked to an aggressive HNSCC phenotype: the rate of
apoptosis is low and the expressions of p53 and VEGF are high. None of the studied biomarkers correlated with
perfusion and hypoxia as evaluated with [15O]H2O-PET and [
18F]FETNIM-PET. Increased tumor metabolism evaluated
with PET may thus signify an aggressive phenotype, which should be taken into account in the management of HNSCC.
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The microenvironment of cancer tissues is very different
from that of healthy tissue. There is uncontrolled forma-
tion of new blood vessels in tumors and this results in
chaotic and heterogeneous tumor vascularization. Conse-
quently, tumor blood flow is variable causing irregular
metabolic gradients, particularly gradients in the oxygen
and glucose concentrations [1]. Blood flow data on human
tumors in situ are scarce, but the few existing studies indi-
cate that the blood flow varies significantly depending
upon tumor type, size and site of growth. A considerable
heterogeneity of flow rates can even be observed in tu-
mors with identical histological classifications [2].
Many human malignancies exhibit hypoxic tissue areas
that are heterogeneously distributed within the tumor
mass; these may be located even adjacent to well-perfused
areas [1]. The initial molecular response to hypoxia is me-
diated through the hypoxia-inducible transcription factor-
1α (HIF-1 α). In the absence of oxygen, HIF-1α binds to
hypoxia-response elements (HREs), thereby activating the
expression of numerous hypoxia-response genes such as
those involved in angiogenesis, glycolysis and oxygen de-
livery. In general, one could say that the cellular response
to hypoxia is intended to prevent cell death and indeed an
increased level of intracellular HIF-1α has been associated
with a poor prognosis and resistance to therapy in cancer
[3]. In addition to the fact that hypoxia upregulates gly-
colysis, classical biochemical studies have shown high
rates of glycolysis in cancer cells, independent of the pres-
ence of oxygen (Warburg’s effect) [4]. The molecular
mechanisms leading to the upregulation of glycolysis in
tumors are still not well understood [5]. In addition to
elevated glycolysis, tumors often show an increased
expression of glucose transporters and/or hexokinase
activity in comparison to normal tissues.
A high metabolic rate indicated by high [18F]FDG uptake
seems to be a predictor of poor outcome for many tumor
types [6]. This predictive capacity might be a consequence
of the fact that the elevated glycolysis encountered in tu-
mors is related to several biological factors associated with
poor prognosis, including hypoxia [7], accelerated cell pro-
liferation [8], inflammation [9] and reduced apoptosis [10].
Hypoxic cells are approximately three-fold more resist-
ant to radiation therapy than well-oxygenated cells. Sev-
eral 18F-labelled 2-nitroimidazole compounds have been
evaluated for their usefulness as hypoxia tracers with
PET [11]. So far, [18F]FMISO is the only one of these
tracers that has widely become used in the clinic. Since
hypoxia is known to increase glycolysis [18F]FDG has
also been proposed as a potential tracer for imaging of
hypoxia. Although increased uptake of [18F]FDG might
indicate the presence of some degree of hypoxia [7]
[18F]FDG has not proved to function as a surrogate
tracer for hypoxia [12].We have previously described the pharmacokinetic
properties of [18F]FETNIM as a hypoxia tracer in experi-
mental tumors [13,14] and in patients with squamous-cell
carcinoma of the head and neck (HNSCC) [12,15,16]. [18F]
FETNIM PET studies in patients with HNSCC were com-
bined with blood flow measurements utilizing [15O]H2O
and [18F]FDG. Although [18F]FETNIM showed a lower
and more favorable background signal than [18F]FMISO
[14], the high hydrophilicity of [18F]FETNIM led to early
tumor uptake, which was largely perfusion dependent up
to 90 min post injection [15]. Generally, a 5- to 30-fold
greater blood flow was seen in tumor than in muscle. A
high uptake of [18F]FETNIM prior to radiation therapy
was associated with a trend towards poor overall sur-
vival, whereas [18F]FDG SUV (p =0.028) and blood flow
(p =0.018) were clearly associated with poor patient
survival [12].
To gain a wider knowledge of the physiological and
pathological changes behind the uptake of tracers believed
to describe glucose metabolism, hypoxia and blood flow,
we compared the expression of multiple biochemical
biomarkers with the uptake of [18F]FETNIM, [18F]FDG
and [15O]H2O as well as the patient outcome in patients
with HNSCC. Immunohistochemistry and in situ methods
were used to determine the expression of the glucose
transporter (GLUT-1), hypoxia-inducible transcription
factor-1 (HIF-1α), vascular endothelial growth factor
(VEGF), microvessel density (CD31), macrophages (CD68),
proliferation (Ki-67), p53 expression and apoptosis (Tunel)
in biopsy samples from patients who had earlier partici-
pated in a multitracer PET study [12]. All of the selected
biomarkers are endogenous molecules that might be in-
volved in, or influence, the underlying biological pathways
responsible for the uptake of the investigated tracers. In
addition, the expression of these selected biomarkers was
correlated with patient outcome.
Methods
Patients and tissues
The PET study protocol and the consent form were ap-
proved by the ethics committee of the Turku University
Central Hospital and permission to use [18F]FETNIM in
patient studies was granted by the Finnish National
Agency for Medicines. All patients provided written in-
formed consent before entering the study. All PET stud-
ies were performed before any oncologic treatment was
given. The use of tumor samples for molecular analysis
was approved by the National Authority for Medicolegal
Affairs.
Fifteen patients with newly diagnosed head and neck
carcinoma (tumor category T1-T4) and with a variety
of primary tumor site presentations participated in the
study (Table 1). All patients were part of an earlier study
on 21 head and neck cancer patients imaged with
Table 1 Characteristics of patients with HNSCC
Patient no. Tumor site TNM at diagnosis Tumor stage Differentiation Type and doses of RT (Gy) Survival in months
1 supraglottic larynx T1N0M0 I well definitive/68.7 28*
2 supraglottic larynx T2N0M0 II moderate definitive/70.0 52*
3 oral cavity T3N2M0 IV poor preoperative/63.4 4*
4 oral cavity T4N1M0 IV moderate preoperative/62.3 10*
5 hypopharynx T1N3M0 IV poor preoperative/62.3 32*
6 oral cavity T4N2M0 IV moderate preoperative/63.0 17*
7 glottic larynx T2N0M0 II moderate definitive/70.0 64
8 hypopharynx T4N1M0 IV poor preoperative/44.0 7*
9 oropharynx T3N2M0 IV moderate preoperative/60.0 12*
10 oral cavity T2N0M0 II well preoperative/64.6 63
11 nasopharynx T3N0M0 III poor preoperative/63.6 70
12 nasopharynx T3N2M0 III poor definitive/68.4 59
13 oropharynx T1N2M0 IV moderate preoperative/62.4 59
14 oropharynx T4N2M0 IV moderate preoperative/61.5 6*
15 oral cavity T2N0M0 II poor preoperative/64.0 58
*Patients are no longer alive.
RT = radiotherapy.
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tients with histologically confirmed squamous cell car-
cinoma and representative biopsy material were included
in this study. Excisional biopsies were taken from the pa-
tients during panendoscopy by a specialist in otolaryn-
gology. The otolaryngologist who obtained samples was
blinded to the imaging results and not involved in the
study at any other level. The maximum time elapsing
between extraction of tumor biopsies and the performed
PET scans was 30 days (median 19, range 7–30). All pa-
tients received either definitive or preoperative external
beam radiotherapy (RT) at doses ranging from 60 to 70 Gy
(Table 1). Two patients (Patients 12 and 14) received con-
comitant chemotherapy consisting of cisplatin and fluoro-
uracil. Paraffin-embedded tissue blocks of formalin-fixed
samples were processed for histological study and immu-
nohistochemical analysis. After treatment, the patients
were followed until December 2005 or death. The median
follow-up time after the diagnosis of cancer was 32 months
(range 26–35).
PET imaging and image analysis
The syntheses of [18F]FDG, [18F]FETNIM and [15O]H2O
have been described previously [13,15]. The PET studies
were performed with a GE Advance PET scanner (General
Electric Medical Systems, Milwaukee, WI, USA) operated
in 2D mode. PET acquisition and image analysis have been
described previously in detail [12].
In short, [18F]FDG was injected intravenously as a 15 sec-
ond bolus (median dose 371 MBq, range 355–385 MBq)
and a static emission scan consisting of three 5 min frames
was acquired 45–60 min after the injection followed by a10 min transmission scan. Dynamic [18F]FETNIM (median
dose 368 MBq, range 289–385 MBq) studies were per-
formed sequentially i.e. after the blood flow measurements
using [15O]H2O (median dose 1150 MBq, range 821–
1800 MBq).
[18F]FDG accumulation was measured as a standard-
ized uptake value (SUV). Regions of interest (ROIs) were
drawn into the time frame between 55 and 60 min after
the injection. Tumor ROIs were defined by an isodensity
contour tool using SUV of 4 as the threshold value.
When necessary, parallel reading of corresponding axial
computer tomography (CT) scans and/or clinical infor-
mation was available in defining the tumor area. Vol-
umes of these ROIs in all planes where the tumor was
visible were summed to obtain the metabolically active
volume of the tumor, which is known to correlate
strongly with the volume determined by CT [17]. The
plane with the highest 3 × 3 pixel (7.04 × 7.04 mm)
maximum SUV, and two adjacent planes were carefully
matched with the corresponding planes on the flow and
[18F]FETNIM images. From [18F]FETNIM images, tumor-
to-plasma ratios (T/P ratio) were calculated using data ac-
quired 90 – 120 min after injection of tracer. The fractional
hypoxic volume (FHV) of the tumor was determined in
the following way. Large ROIs were first drawn in three ad-
jacent planes in brain, muscle and lung tissues of 3 patients
each. Secondly, tissue-to-plasma radioactivity ratios of all
individual pixels (n =10968) in all these planes were
pooled. Thirdly, the threshold for hypoxia was set at three
standard deviations above the mean of these normal
tissue-to-plasma activity ratios (=0.93). Finally, the per-
centage of pixels in whole tumor ROI above this ratio of
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measured with [15O]H2O utilizing the autoradiographic
method using a 250-sec integration time and an arterial
input curve. The process has been described in detail
previously [15]. PET scans were analyzed by KL under the
supervision of HM. In case of discrepancies a consensus
reading was performed. Quantitative image analysis was
done by KL and VO.
Histology and immunohistochemistry
The necrotic tumor volume, degree of inflammation and
estimates of mitoses, macrophages and apoptosis were
obtained from hematoxylin-eosin stained tumor sections
by conventional histological evaluation.
Immunohistochemistry was performed on 4-μm thick
tissue sections. After deparaffination and rehydration,
endogenous peroxidase activity was blocked for 30 mi-
nutes in an aqueous solution containing 0.3% hydrogen
peroxide. Antigen retrieval was carried out in a micro-
wave oven. The sections were then incubated with the
primary antibody for 25 minutes at room temperature
(RT). Visualization of primary antibodies was done with
Vectastain ABC reagent and diaminobenzidine substrate
kit (Vector Laboratories, Burlingame, CO), which is based
on an indirect streptavidin-biotin method. The slides
were later counterstained with hematoxylin. The anti-
bodies and dilutions used were as follows: GLUT-1
(DAKO, Carpinteria, CA; dilution 1:200), VEGFsc-152
(Santa Cruz Biotechnology, Santa Cruz, CA; dilution
1:200) and HIF-1α (BD Transduction Laboratories, San
Jose, CA; dilution 1:100). The staining for Ki-67 (DAKO;
dilution 1:100), p53 (DAKO; dilution 1:300), CD31 (Bio-
Genex, San Ramon, CA; dilution 1:2) and CD68 (DAKO;
dilution 1:100) was done using the TechMate 500 immu-
nostainer and a peroxidase/diaminobenzidine multilink
detection kit (DAKO). Appropriate positive controls were
used throughout the studies.
In situ detection of apoptotic cells (TUNEL)
In situ detection of apoptotic cells in paraffin wax sec-
tions was performed as described earlier [18] with slight
modifications. Briefly, endogenous peroxidase activity was
blocked and DNA 3`-end-labeling was performed with
terminal transferase buffer (Promega, Madison, WI). The
reaction was allowed to continue for 1 hr at 37°C in a
humidified chamber. Slides were then incubated with
blocking buffer containing 2% blocking reagent and 0.05%
sodium azide (Boehringer) for 30 min. Antidigoxigenin
antibody, conjugated to alkaline phosphatase (1:2000,
Boehringer), in 2% blocking buffer was added and incu-
bated for 2 hr. The slides were treated with alkaline
phosphatase buffer for 10 min. Thereafter, 337 mg/ml
nitroblue tetrazolium salt (Boehringer) and 175 mg/ml
5-bromo-4-chloro-3-indoylphosphate (Boehringer) wereadded in fresh alkaline phosphatase buffer, and the reaction
was terminated 3 hr and 45 min later by addition of 1 mM
EDTA and 10 mM Tris–HCl, pH 8.0. Finally, slides were
mounted with Gurr Aquamount (BDH Chemicals, Poole,
UK). For controls, terminal transferase, dig-ddUTP, or
antidigoxigenin antibody were omitted from the reaction.
Data analysis
An experienced pathologist examined the hematoxylin-
eosin stained samples and was blind to all other bio-
markers and PET parameters. The percentage of necrotic
tumor volume was estimated and the degree of inflam-
mation and the amount of mitoses, macrophages and
apoptoses was semiquantitatively scored as none, slight,
moderate or severe.
All immunohistochemical analyses were conducted by
two independent observers who were unaware of the
PET data. All sections were first evaluated with a ×20
objective as to provide an estimation of cells showing
staining in the whole sample. The most representative
tumor area was identified and a quantitative assessment
of the percentage of cells showing nuclear staining in
the ×40 objective in three separate optical fields in a
total of 300 carcinoma cells was calculated from sections
stained for p53 expression. The percentage of cells show-
ing staining in the cytoplasm was calculated for CD68 in a
similar manner. For HIF-1, similar calculations were done
in hot spot areas showing nuclear staining. In this study,
we counted the Ki-67 expression from a total of 300 car-
cinoma cells in invasive regions only. Tumor cells were
considered positive for GLUT-1 expression whenever an
even slight netlike membrane staining was present regard-
less of the degree of the cytoplasmic staining pattern.
Again, the percentage of positive cells from a total of 300
carcinoma cells was calculated. Tumor cells showing
VEGFsc-152 staining in the cytoplasm was scored according
to the intensity of the staining as weak, moderate or
intense depending on the area within the tumor that re-
vealed the most intense staining (hot spot). For further
analysis tumors were divided into two groups that repre-
sented tumors with weak staining (n =6) and intense
(moderate or strong) staining (n =9). Within the CD31
stained slides, the microvessel hot spot area was identified
and microvessels were counted with ×40 magnification
and expressed as a percentage of vessels per square
millimetre.
Apoptotic cells detected with Tunel were counted
from tumor sections stained with the antidigoxigenin
antibody. The presence of a distinct intensely dark color
reaction within tumor cells was regarded as representing
apoptotic DNA fragmentation. The results are expressed
as number of positive cells per millimetre squared when
a ×10 objective lens was used. In situ detection of free
DNA 3’-ends is a well-established method for the
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idated by simultaneous electrophoretic DNA analysis in
pancreatic tissue [18].
Statistical analyses
Statistical analyses were performed with SAS System
software (Service Pack 2), version 9.1.3 (SAS Institute,
Cary, NC, USA). Nonparametric tests were used through-
out since the assumption of normality was violated in
some parameters. Spearman’s correlation coefficient (rs)
was used to correlate PET parameters with histological
findings. Due to the limited sample size, no adjustment
for simultaneous testing of multiple variables was per-
formed. The Wilcoxon rank sum test was used to
compare histological findings in PET parameter groups
(dichotomized using the median as the cut point) and
clinical outcome. The limit for statistical significance
was set at p <0.05.
Results
Relationship between PET findings and
immunohistochemistry
The immunostaining displayed a heterogeneous expression
pattern. The median (range) of positive stained cells ana-
lyzed from samples was 40% (17 – 87%) for Ki-67, 25%
(0 – 60%) for GLUT-1, 70% (2 – 95%) for p53, 16% (0 –
68%) for HIF-1α, 27% (5 - 44%) for CD68, 3% (0.4 –Table 2 Quantitative analyses of PET findings using three tra
[18F]FDG
















Mean ± SD 13.8 ± 6.5 51.8 ± 103.2 3
Median (range) 13.0 (5.3 – 28.8) 12.6 (1.4 – 401.6) 48.0
astandardized uptake value.
bmetabolically active volume as determined from [18F]FDG PET.
cfractional hypoxic volume.
dmaximum tumor-to-plasma radioactivity at 90 – 120 min.14.9%) for CD31 and 10% (0.3 – 20%) for apoptosis as
detected with the Tunel method.
Individual PET findings for the 15 patients are pre-
sented in Table 2 and biomarker findings in Table 3.
Spearman’s correlation coefficients (rs) and p-values were
calculated from PET for the relationship between [18F]
FDG, [18F]FETNIM or [15O]H2O, and the expression of
biomarkers (Table 4). When the tracer uptake indices
were treated as continuous variables no correlation could
be detected between the PET data and any of the en-
dogenous biomarkers, although the expression of p53
showed a trend toward a correlation with [18F]FDG SUV
(rs =0.470, p =0.078), as shown in Table 4.
The PET uptake indices were further divided into
values either less than or equal to the median value
(Table 2) or values greater than the median value and
associated with the expression of biomarkers. As shown
in Figure 1A, the tendency toward an association be-
tween the expression of p53 and [18F]FDG SUV now
became statistically significant (p =0.029). There was
also a trend that the amount of apoptotic cells would be
associated (p =0.094) with [18F]FDG SUV (Figure 1B).
The metabolically active tumor volume, on the other hand,
was inversely associated (p =0.029) with the numbers of
apoptotic cells (Figure 1C). The expression of the prolifera-
tive marker Ki-67 also showed a clear tendency toward an
association (p =0.090) with tumor volume values less thancers in patients with HNSCC
[18F]FETNIM [15O]H2O
















9.8 ± 21.1 1.17 ± 0.32 33.1 ± 12.7
(9.5 – 63.2) 1.10 (0.72 – 1.98) 30.4 (12.4 – 63.1)
Table 3 Biomarker findings from individual patients
Patient Ki-67 Glut-1 p53 Hif-1α CD68 CD31 Tunel VEGFSC-152
no. % % % % % % % Intensity
1 17 5 70 0 27 2.5 19 3
2 36 30 90 52 5 0.4 6 2
3 82 10 80 16 26 0.6 10 2
4 18 5 40 10 16 1.8 17 1
5 60 5 95 0 13 5.7 0.3 2
6 35 20 75 0 14 6.0 11 1
7 85 40 25 58 7 6.8 10 2
8 86 60 80 41 30 6.2 7 1
9 87 60 5 33 33 1.6 6 3
10 28 0 75 1 30 2.6 n.d 1
11 80 0 90 1 38 4.7 7 2
12 n.d n.d 65 68 44 2.6 16 3
13 n.d 50 30 34 27 3.0 20 1
14 35 50 2 23 9 14.9 10 2
15 40 60 2 1 37 7.3 15 1
Median 40 25 70 16 27 3 10
Range 17-87 0-60 2-95 0-68 5-44 0.4-14.9 0.3-20
n.d. = not determined.
Grönroos et al. BMC Cancer 2014, 14:876 Page 6 of 11
http://www.biomedcentral.com/1471-2407/14/876or equal to the median and values greater than the median
value (Figure 1D). The expression of VEGF in tumors was
analyzed by staining intensity and a significant association
was observed with [18F]FDG SUV (p =0.036), but not with
the other PET parameters (Figure 1E).
Correlations of biomarker expression
There were significant correlations detected between
the expressions of some of the biomarkers. As shown in
Figure 2A, the expression of HIF-1α correlated with the
expression of GLUT-1 (r =0.553, p =0.040). The expressionTable 4 Correlations between endogenous biomarkers and PE
[18F]FDG
SUVa Tumor volumeb (cm3) FHV
rs p rs p rs
GLUT-1 - 0.166 0.577 - 0.064 0.831 0.333
HIF-1α - 0.194 0.496 - 0.281 0.318 - 0.151
Ki-67 0.084 0.781 0.172 0.565 0
p53 0.470 0.078 0.428 0.113 - 0.269
CD-31 - 0.114 0.691 0.139 0.627 0.314
CD-68 - 0.046 0.872 - 0.007 0.980 0.039
Tunel - 0.414 0.127 - 0.386 0.159 - 0.064
astandardized uptake value.
bmetabolically active volume as determined from [18F]FDG PET.
cfractional hypoxic volume.
dmaximum tumor-to-plasma radioactivity at 90 – 120 min.
rs = Spearman correlation coefficients.
p = p-value.of p53 correlated inversely (r = −0.618, p =0.019) with the
expression of GLUT-1 (Figure 2B). There was also a nega-
tive correlation (r = −0.638, p =0.014) between proliferation
assessed with Ki-67 and the numbers of apoptotic cells
(Figure 2C). There was a trend toward a significant
correlation (r =0.506, p =0.065) between the expres-
sions of Ki-67 and HIF-1α (Figure 2D).
Association between biomarkers and patient outcome
Patient outcome data was available for all patients. At
the end of follow-up period, 6 patients were alive and 9T parameters analyzed from patients with HNSCC
[18F]FETNIM [15O]H20
c (%) T/P ratiod Blood flow (ml/100 mg/min)
p rs p rs p
0.251 - 0.084 0.779 - 0.042 0.895
0.598 - 0.345 0.212 - 0.237 0.383
1 - 0.046 0.878 - 0.327 0.282
0.340 0.074 0.799 0.020 0.948
0.260 0.164 0.566 - 0.360 0.158
0.892 - 0.093 0.747 - 0.086 0.776
0.824 - 0.125 0.663 0.072 0.810
p = 0.029
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Figure 1 Relationship between PET findings and immunohistochemistry. Association between the expression of p53 (A) and the amount of
apoptotic cells (B) with [18F]FDG SUV (●, lower SUV; ○, higher SUV). The amount of apoptotic cells displayed an association with the metabolically
active tumor volume (C) and a trend toward an association in the expression of Ki-67 was also seen with the metabolically active tumor volume
(D) (●, values less than or equal to the median value; ○, values greater than the median value). In E, the association between VEGF expression
and [18F]FDG SUV is illustrated as ●, weak expression; ○, intense expression.
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CD68 was associated with overall survival (p =0.050)
(Figure 3).Discussion
The rational application of hypoxia imaging and
hypoxia-directed treatment strategies in oncology has
to be based on a fundamental understanding of the
biochemical and molecular biological processes that
govern the uptake of a given PET tracer. Our study
design enabled us to investigate the relationship between
protein markers and the uptake of tracers used to image
hypoxia, glucose metabolism and blood flow in patients
with HNSCC.[18F]FETNIM uptake, blood flow and biomarker expression
One of our main finding in this study was that the up-
take of [18F]FETNIM did not correlate with the expres-
sion of HIF-1α, nor with any other biomarker analyzed.
Similarly, no correlation was seen for blood flow, as
assessed using [15O]H2O, and the expression of the bio-
markers depicting the vascular status.
The expression of HIF-1α is elevated in response to
hypoxia. HIF-1α induces the expression of hundreds of
target genes; those regulating angiogenesis and glucose
metabolism are some of the most important with respect
to cancer growth [3]. HIF-1α seems to respond not only
to hypoxia, but also rapidly to reoxygenation. If this is
the case, then HIF-1α may be an unreliable measure of
hypoxia in the context of clinical sample collection. Even
p = 0.040     r = 0.553
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p = 0.014     r = - 0.638



















p = 0.065     r = 0.506















Figure 2 Correlations of biomarker expression. A correlation was detected between the expressions of HIF-1α and GLUT-1 (A). The expression
of p53 showed a negative correlation with the expression of GLUT-1 (B) and the amount of apoptosis with Ki-67 (C). Furthermore, the expression
of Ki-67 displayed a borderline correlation with that of HIF-1α (D).
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exogenous markers, such as pimonidazole or EF5, and
the uptake of hypoxia radiotracers [19,20], a poor match
between the pimonidazole localization and the distribu-
tion of HIF-1α target proteins has been reported [21-23].

















Figure 3 Association between CD68 and patient outcome. There
was a relationship observed between survival status of patients and
the expression of CD68 HNSCC, indicating that an increased rate of
macrophage infiltration into tumors was associated with a poor
prognosis in patients with HNSCC.between HIF-1α expression and [18F]FMISO uptake.
However, recently two papers reported on a significant
correlation between the uptake of [18F]FMISO and HIF-
1α expression [24,25] as well as the expression of p53
[25] in HNC. HIF-1α overexpression has also been asso-
ciated with increased proliferation and p53 expression
in invasive breast cancer [26]. In our study, the expres-
sion of HIF-1α tended to correlate (rs =0.506, p =0.065)
with the expression of Ki-67 (Figure 2D), but not with
that of p53. The association between HIF-1α and prolifer-
ation is not fully understood - perhaps HIF-1α may either
reflect or react to tumor proliferation.
[18F]FDG uptake and GLUT-1 expression
A number of studies have examined the relationship be-
tween GLUT-1 expression and the uptake of [18F]FDG in
head and neck cancer. In the present study, the [18F]FDG
uptake expressed as SUV did not correlate (rs = -0.166,
p =0.577) with the expression of GLUT-1. The lack in
correlation between GLUT-1 and [18F]FDG SUV has
also been reported by others [27-29] in patients with
squamous cell carcinoma. On the other hand, other
groups have described a positive correlation between
[18F]FDG SUV and GLUT-1 expression [30-34]. These
conflicting findings might, at least partly, depend on the
scoring method applied for quantification and hence
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for other biomarker analyses performed in this study.
In the current study, only cell membrane staining was
accounted for regardless of the degree of the cytoplasmic
staining pattern or the staining intensity of GLUT-1.
Relationship between p53, apoptosis, cell proliferation
and [18F]FDG
Disruption of apoptosis control can lead to unlimited
cell growth and promote carcinogenesis. p53 is one of
the most important genes in the regulation of apoptosis.
A number of studies have shown that overexpression of
mutated p53 protein is associated with poor overall sur-
vival in patients with HNSCC [35]. We found a signifi-
cant association (p =0.029) between p53 expression and
the uptake of [18F]FDG expressed as SUV (Figure 1A).
We also detected a negative association (p =0.029) be-
tween the numbers of apoptotic cells and the metabolic-
ally active tumor volume (Figure 1C). Studies on epithelial
tumors have indicated that tumors with higher apoptotic
rates have better prognoses than those with lower rates
[36]. Our results revealed higher numbers of cells in apop-
tosis in smaller tumors (Figure 1C), which furthermore
showed a trend toward an association (p =0.094) with a
lower [18F]FDG SUV (Figure 1B). In line with these
findings, higher amounts of apoptotic cells correlated
(rs = −0.638, p =0.014) with a lower expression of the
proliferative marker Ki-67 (Figure 2C). In summary, our
results indicate that tumors with a higher apoptotic rate
and reduced p53 expression are less aggressive.
Studies in esophageal cancer [37] and HNSCC [38]
with Ki-67 reported that there was a correlation between
[18F]FDG SUV and Ki-67 but there have also been
contradictory studies where no correlation of prolifera-
tion with [18F]FDG SUV has been observed [39,40]. In
our study, there was no correlation between these two
parameters. However, a tendency toward a higher ex-
pression of Ki-67 in larger tumors was seen as measured
from the metabolically active tumor volume with [18F]
FDG, but the relationship did not reach statistical sig-
nificance (p =0.090). Thus, current evidence indicates
that while proliferation may contribute to glucose me-
tabolism it is not strongly linked to an increased uptake
of [18F]FDG and, thus, not glucose.
Relationship between VEGF and [18F]FDG
The expression of VEGF may also stimulate the uptake
of [18F]FDG in endothelial cells in vitro [41], but this
claim has been criticized [26]. Immunohistochemical
staining of the VEGF receptor correlates significantly
with the uptake of both [18F]FDG and [18F]FMISO in
brain tumors [42]. In a study conducted in esophageal
squamous cell cancer patients, the SUVmax correlated
with the VEGF expression level [43], whereas no suchcorrelation was found in the studies of Taylor et al. [44]
and Westerterp et al. [45]. In the current work, there
was a positive association (p =0.036) between the stain-
ing intensity of VEGF and [18F]FDG SUV (Figure 1E),
but not with [18F]FETNIM.
Relationship between biological markers and outcome
Only the expression of macrophages (as measured by
CD68 staining) was associated with patient outcome.
The amount of CD68 positive cells was higher among
the surviving patients than among those who died of
HNSCC (p =0.050). This finding is in support of the re-
sults of a study where the primary tumor macrophage
content was a strong predictor of tumor aggressiveness
in HNSCC [46]. Although the uptake of [18F]FDG could
reflect the macrophage content in tumor tissue, we were
not able to detect any relationship between these two
parameters.
One limitation of the current study, or any study that
attempts to correlate PET findings with the expression
of biomarkers, is the comparison of findings on a micro-
scopic level (micrometer range) with the PET signal
where the resolution is in millimeter range. Further-
more, it is questionable whether the uptake of [18F]FDG
or [18F]FETNIM can reflect only one molecular or cellu-
lar rate-limiting step, as e.g. the expression of Glut-1
and HIF-1α.
Conclusions
A high uptake of [18F]FDG expressed as SUV is linked
to an aggressive HNSCC phenotype: the rate of apop-
tosis is low and the expression of p53 and VEGF is
high. None of the studied biomarkers correlated with
perfusion and hypoxia evaluated with [15O]H2O-PET
and [18F]FETNIM-PET, respectively. Estimates of the
biomarkers showed that Ki-67 expression was inversely
associated with the apoptotic rate, which further sup-
ports the concept that the apoptotic rate reflects the
prognosis.
In conclusion, [18F]FDG uptake is associated with the
expression of p53 and with apoptosis in HNSCC. Still,
the overall uptake of a tracer into HNSCC is clearly the
net sum of multiple mechanisms, since no other associa-
tions were detected, e.g., there were no statistically sig-
nificant correlations found between [18F]FETNIM-PET
and HIF-1α, [15O]H2O-PET and microvessel density. Re-
search in this area is warranted to clarify the molecular
pathways underlying tracer uptake.
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